Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus

Moon, Min Kyong; Hur, Kyu Yeon; Ko, Seung Hyun; Park, Seok O; Lee, Byung Wan; Kim, Jin Hwa; Rhee, Sang Youl; Kim, Hyun Jin; Choi, Kyung Mook; Kim, Nan Hee

doi:10.3904/kjim.2017.354

Cited by 25 publications

(16 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although, concerns regarding cardiovascular safety after use of DPP-4 inhibitors are persisting, many studies did not show any increased risk in type-2 diabetic management, after treating with DPP-4 inhibitors [22][23][24]. The clinical practice guidelines and use of oral antihyperglycaemic agents for adult patients must be up-dated with type-2 diabetes for better results similar to the Korean Diabetes Association [25].…”

Section: Discussionmentioning

confidence: 99%

Comparative Study of Incretin Versus Non- Incretin Based Therapies on Type 2 Diabetes Patients in Addis Ababa, Ethiopia

Tesfamariam¹,

Menon

Kebede

et al. 2018

View full text Add to dashboard Cite

Type 2 diabetes is characterized by hyperglycemia due to defects in insulin secretion or insulin action. Over the years, attempts to regulate diabetics therapeutically through glycemic control have reduced complications and trauma associated with the disease. Aim of this study was to compare efficacy of incretin-based versus non-incretin based therapies on type-2 diabetic patients and a hospital based cross-sectional comparative study was conducted. Sixty type-2 diabetic patients who received non-incretin and thirty who received incretin based therapies were randomly selected for the study. The mean total cholesterol, triglyceride, low density lipoprotein, serum urea and serum creatinine were significantly lower in patients who received incretin-based therapies than those who received non-incretin based therapies. The mean high density lipoprotein was also significantly increased among the incretin based treated group. The mean body mass index and fasting blood sugar were lower in the incretin-based compared to non-incretin based treated patients. Female had insignificantly higher level of blood sugar, triglyceride, low density lipoprotein, serum urea, body mass index and lower level of total cholesterol, high density lipoprotein and serum creatinine compared to male in both groups. Incretin-based therapy helps normalize lipid profiles, blood sugar level, body mass index and also improves kidney clearance pattern.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Study of Incretin Versus Non- Incretin Based Therapies on Type 2 Diabetes Patients in Addis Ababa, Ethiopia

Tesfamariam¹,

Menon

Kebede

et al. 2018

View full text Add to dashboard Cite

show abstract

“…To increase the comparability, matched controls were selected based on incidence density sampling which involved in matching each AECOPD case to a sample of those potential controls who were at risk at the time of case occurrence, resulting obtaining unbiased estimates of relative risk. Before matching, we additionally excluded the patients had monotherapy and then included subjects with double or triple combination therapy of OADs which regimen were validated by clinical trials and meta-analyses (14). Finally, each case was matched to 4 randomly selected controls according to the propensity score estimation by sex, age, the year of COPD diagnosis, the initial year of DM status, previous and coexisting disease conditions, Charlson comorbidity index (CCI), level complexity of COPD and the COPD medication use three month prior to the date of AECOPD.…”

Section: Case and Control Patient Selectionmentioning

confidence: 99%

Combination Therapies with Thiazolidinediones are Associated with a Lower Risk of Acute Exacerbations in New-Onset COPD Patients with Advanced Diabetic Mellitus: A Nested Case-Control Study

Chen

Tseng

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND: The effects of oral antihyperglycemic drugs (OADs) for T2DM on outcomes of co-existing COPD patients have been less concerned. We examined the association of combinational OADs and risk of AECOPD in T2DM patients with co-existing COPDMETHODS: A nested case-control study was conducted using data from the National Health Insurance Research Database of Taiwan. Among new-onset COPD-T2DM patients, 65,370 were prescribed with metformin and 2nd line OADs before the date of COPD onset. Each AECOPD case was matched to 4 randomly selected controls according to the propensity score estimated by patient’s baseline characteristics. Conditional logistic regression analysis was performed to estimate the association between AECOPD risk and OADs use. RESULTS: Among COPD-T2DM patients, 3,355 AECOPD cases and 13,420 matched controls were selected. All COPD-T2DM patients with a double combination of oral OADs (n=12,916), AECOPD patients were less likely to be exposed to SU and thiazolidinediones (TZD) compared to the patients received metformin (MET) and sulfonylurea (SU), with an adjusted odds ratio (OR) of 0.69 (95% confidence interval [CI]: 0.51–0.94, P=0.02). Of the patients with a triple combination of oral OADs (n=3,859), we found that MET, SU and TZD had a lower risk of AECOPD (adjusted OR=0.81 (0.68-0.96, P=0.01) compared to a combination of MET, SU and a-glucosidase inhibitors (AGI) regardless the level of COPD complexity. CONCLUSION: Combination therapies with TZD were associated with reducing risk of AECOPD in advanced T2DM patients with co-existing COPD.

show abstract

“…In the present study, the incidence of hypoglycemic symptoms was 3.33% in both groups. According to one meta-analysis, there was 50% chance of hypoglycemic symptoms when DPP-4 inhibitor was added to sulfonylurea, compared with placebo added to a sulfonylurea [33]. As per one meta-analysis of teneligliptin, the use of second-line therapy used with caution due to the risk of hypoglycemia, weight gain, and lower durability of glycemic response [24].…”

Section: Safety Assessmentmentioning

confidence: 99%

“…As per one meta-analysis of teneligliptin, the use of second-line therapy used with caution due to the risk of hypoglycemia, weight gain, and lower durability of glycemic response [24]. The selection of antidiabetic medications for combination therapy depends on the patient's characteristics, efficacy of initial medicine, and cardiovascular benefit [33]. Another network meta-analysis result suggested that DPP-4 inhibitors appear to be a tolerable option for patients with T2DM with low incidence of GI AE compared to other combinations [34].…”

Section: Safety Assessmentmentioning

confidence: 99%

Efficacy and Safety of Teneligliptin as Add-on Therapy to Conventional Therapy in Indian Patients With Type 2 Diabetes Mellitus

2019

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Teneligliptin is a novel, highly selective dipeptidyl peptidase-4 inhibitor. The objective of the present study was to investigate the efficacy and safety of teneligliptin as add-on therapy in patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled by conventional therapy (metformin/glimepiride) in India. Methods: Clinical study protocol was approved by the Institutional Ethics Committee. T2DM patients (male/female) whose glycated hemoglobin (HbA1c) >7% were randomized to receive following group treatments, namely, Treatment A: Metformin/glimepiride plus add-on teneligliptin 20 mg and Treatment B: Metformin/glimepiride for 24 weeks. A pre-designed case report form was used to collect information from the prescribing physicians regarding the efficacy and safety of teneligliptin. Efficacy variables included change in plasma blood glucose (fasting and postprandial) and HbA1c from baseline to week 24. Treatment emergent adverse events were assessed. Results: A total of 120 type 2 diabetes patients were analyzed. Teneligliptin as add-on therapy with metformin/glimepiride significantly reduced plasma glucose (HbA1c, fasting, and postprandial) concentration as compared to conventional therapy. Conclusion: Add-on therapy with teneligliptin was found superior over conventional therapy in reducing plasma glucose concentration (fasting and postprandial) and HbA1c levels significantly in patients with T2DM. Further, it was found effective and well tolerated in Indian patients with T2DM who are inadequately controlled with conventional therapy.

show abstract

Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus

Cited by 25 publications

References 45 publications

Comparative Study of Incretin Versus Non- Incretin Based Therapies on Type 2 Diabetes Patients in Addis Ababa, Ethiopia

Comparative Study of Incretin Versus Non- Incretin Based Therapies on Type 2 Diabetes Patients in Addis Ababa, Ethiopia

Combination Therapies with Thiazolidinediones are Associated with a Lower Risk of Acute Exacerbations in New-Onset COPD Patients with Advanced Diabetic Mellitus: A Nested Case-Control Study

Efficacy and Safety of Teneligliptin as Add-on Therapy to Conventional Therapy in Indian Patients With Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About